Rti Surgical, Inc.

Regeneration Technologies, Inc.

Rti Biologics, Inc.

C Randal Mills

John R Bianchi

Chandrasekaran Nataraj

Michael R Roberts

David T Cheung

John W Howell, Jr

John F Wironen

Sean Hanstke

Kevin C Carter

Jamie M Grooms

Michael Esch

Russell S Donda

P J Gorham

Pat Coleman

Kevin Ross

Wesley I Lewis

Dayna Buskirk

Harry Rambo

Harry W Rambo

Darren G Jones

Michael J Zingaro

Benjamin R Sanders

The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic gent to attract a desired cell.

Connective-tissue-based or dermal-tissue-based grafts/implants

This invention is directed to an assembled implant comprising two or more portions of bone that are held together in appropriate juxtaposition with one or more biocompatible pins to form a graft unit. Preferably, the pins are cortical bone pins. Typically, the cortical pins are press-fitted into appropriately sized holes in the bone portions to achieve an interference fit. The bone portions are allograft or xenograft.

Assembled implant

This invention is a novel method for perfusion of a porous implant which achieves efficient interpenetration of desired factors into and removal of undesirable factors from the pores of the implant, cleaning of the implant, efficient passivation of the implant (inactivation of pathogens, microorganisms, cells, viruses and the like and reduction in antigenicity thereof), and the novel implant produced by such treatment. The process presents a system wherein the rate of pressure cycling, the fact of pressure cycling, and the amplitude of pressure cycling, results in highly cleaned tissues and other implants for implantation. Target decontamination goals for this process include between about a one (1) to twelve (12) log reduction in bacterial contamination, between about a one (1) to fifteen (15) log reduction in enveloped virus contamination, up to about a five (5) log reduction in non-enveloped virus contamination, between about a two (2) to ten (10) fold reduction in endotoxin, maintenance of implant or graft biologic and biomechanical properties, absence of tissue toxicity due to cleaning solutions used, and reduced implant antigenicity.

Cyclic implant perfusion, cleaning and passivation process and implant produced thereby

The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic agent to attract a desired cell.

Muscle-based grafts/implants

A method for perfusion of a porous implant which achieves efficient interpenetration of desired factors into and removal of undesirable factors from the pores of the implant, cleaning of the implant, efficient passivation of the implant, and the implant produced by such treatment. A system wherein the rate of pressure cycling, the fact of pressure cycling, and the amplitude of pressure cycling, results in highly cleaned tissues and other implants. Goals include between about a one to twelve log reduction in bacterial contamination, between about a one to fifteen log reduction in enveloped virus contamination, up to about a five log reduction in non-enveloped virus contamination, between about a two to tenfold reduction in endotoxin, maintenance of implant or graft biologic and biomechanical properties, absence of tissue toxicity due to cleaning solutions used, and reduced implant antigenicity.

The present invention is directed to the field of implants that include soft tissue. More particularly, the present invention is directed to processes for treating implants that include soft tissues such as tendons and ligaments, and to implants produced by such processes. The present invention is also directed to processes and apparatus for improved processing of implants that include soft tissue, by applying kinematic restraint, preferably tension, to the implant or specific portions of the implants during the treatment, and to implants produced by such processes and apparatus. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity.

Process and apparatus for treating implants comprising soft tissue

The present invention is directed to an intermediate composition for producing a muscle tissue matrix suitable for implantation in humans, comprising shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier, preferably a biocompatible acid solution, to form a muscle tissue slurry having a viscosity within the range of 1 centistoke to 20,000 centistokes measured at 25&#xb0; C. In another aspect, the present invention is directed to a tissue implant comprising a human muscle tissue matrix.

Matrix composition for human grafts/implants

This invention includes a novel method for safely, effectively and efficiently pooling of tissues for treatment prior to implantation into a recipient in need thereof. In one embodiment, the method includes perfusion of a porous implant which achieves efficient interpenetration of desired factors into and removal of undesirable factors from the pores of the implant, cleaning of the implant, efficient passivation of the implant (inactivation of pathogens, microorganisms, cells, viruses and the like and reduction in antigenicity thereof), and the novel implant produced by such treatment. The process presents a system wherein the rate of pressure cycling, the fact of pressure cycling, and the amplitude of pressure cycling, results in highly cleaned tissues and other implants for implantation. Target decontamination goals for this process include between about a one (1) to twelve (12) log reduction in bacterial contamination, between about a one (1) to fifteen (15) log reduction in enveloped virus contamination, up to about a five (5) log reduction in non-enveloped virus contamination, between about a two (2) to ten (10) fold reduction in endotoxin, maintenance of implant or graft biologic and biomechanical properties, absence of tissue toxicity due to cleaning solutions used, and reduced implant antigenicity.

Implant sterilization apparatus

Growing community of inventors

Tioga, FL, United States of America

C Randal Mills